Cargando…
Brca2 deficiency drives gastrointestinal tumor formation and is selectively inhibited by mitomycin C
BRCA2 is crucial for repairing DNA double-strand breaks with high fidelity, and loss of BRCA2 increases the risks of developing breast and ovarian cancers. Herein, we show that BRCA2 is inactively mutated in 10% of gastric and 7% of colorectal adenocarcinomas, and that this inactivation is significa...
Autores principales: | Chen, Xiaomin, Peng, Fangfei, Ji, Yan, Xiang, Honggang, Wang, Xiang, Liu, Tingting, Wang, Heng, Han, Yumin, Wang, Changxu, Zhang, Yongfeng, Kong, Xiangyin, Lang, Jing-Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519908/ https://www.ncbi.nlm.nih.gov/pubmed/32980867 http://dx.doi.org/10.1038/s41419-020-03013-8 |
Ejemplares similares
-
MYC predetermines the sensitivity of gastrointestinal cancer to antifolate drugs through regulating TYMS transcription
por: Liu, Tingting, et al.
Publicado: (2019) -
Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
por: Gorodnova, Tatiana V., et al.
Publicado: (2021) -
Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant
por: Ottey, M, et al.
Publicado: (2004) -
The Effect of Mitomycin C on Reducing Endometrial Fibrosis for Intrauterine Adhesion
por: Xu, Fang, et al.
Publicado: (2020) -
NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation
por: Miao, Kai, et al.
Publicado: (2020)